Population Pharmacokinetics of Liposomal Irinotecan

Number of patents in Portfolio can not be more than 2000

United States of America Patent

SERIAL NO

15598633

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Nal-IRI is a liposomal formulation of irinotecan with a longer half-life (t1/2), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (Cmax) compared with non-liposomal irinotecan.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IPSEN BIOPHARM LTDWREXHAM INDUSTRIAL ESTATE WREXHAM LL13 9UF

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Adiwijaya, Bambang Belmont, US 8 27
Fitzgerald, Jonathan Basil Arlington, US 43 295

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation